Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 10:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 28 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Psoriatic Conditions Clear all
Recruiting Not applicable Interventional Accepts healthy volunteers

Regulation of Mucosal Healing in Inflammatory Bowel Disease

NCT04504136
View directory record Official record
Conditions
Inflammatory Bowel Diseases
Interventions
Serial Biopsy
Procedure
Lead sponsor
Terrence A Barrett
Other
Eligibility
18 Years to 90 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 7, 2025 · Synced Sep 7, 2026, 10:24 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

PatientSpot Formerly Known as ArthritisPower

NCT03840928
View directory record Official record
Conditions
Rheumatoid Arthritis, Ankylosing Spondylitis, Fibromyalgia, Gout, Crohn Disease, Juvenile Idiopathic Arthritis, Lupus Erythematosus, Myositis, Osteoarthritis, Osteoporosis, Psoriasis, Psoriatic Arthritis, Scleroderma, Dermatomyositis, Inflammatory Bowel Diseases, Polymyositis, Axial Spondyloarthritis, Diffuse Idiopathic Skeletal Hyperostosis, Polymyalgia Rheumatica, Giant Cell Arteritis, Temporal Arteritis, Wegener, Relapsing Polychondritis, Undifferentiated Connective Tissue Disease, Spinal Cord Injuries, Alzheimer Disease, Amyotrophic Lateral Sclerosis, Ataxia, Bell Palsy, Brain Tumor, Cerebral Aneurysm, Epilepsy, Guillain-Barre Syndrome, Headache, Head Injury, Hydrocephalus, Lumbar Disc Disease, Meningitis, Multiple Sclerosis, Muscular Dystrophy, Neurocutaneous Syndromes, Parkinson Disease, Stroke, Cluster Headache, Tension-Type Headache, Chronic Obstructive Pulmonary Disease, Asthma, Lung Cancer, Cystic Fibrosis, Sleep Apnea, Eczema, Alopecia, Chronic Inflammation, Unstable Angina, Heart Attack, Heart Failure, Arrythmia, Valve Heart Disease, High Blood Pressure, Congenital Heart Disease, Peripheral Arterial Disease, Diabetes, Chronic Liver Disease, Obesity
Interventions
Not listed
Lead sponsor
Global Healthy Living Foundation
Other
Eligibility
19 Years and older
Enrollment
40,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2025
U.S. locations
1
States / cities
Upper Nyack, New York
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Sep 7, 2026, 10:24 AM EDT
Completed Phase 3 Interventional

Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight

NCT06588296
View directory record Official record
Conditions
Psoriatic Arthritis, Obesity
Interventions
Ixekizumab, Tirzepatide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
279 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
81
States / cities
Avondale, Arizona • Chandler, Arizona • Flagstaff, Arizona + 75 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Sep 7, 2026, 10:24 AM EDT
Completed Phase 3 Interventional Results available

PALACE 3: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis

NCT01212770
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Apremilast 20mg, Apremilast 30mg, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
505 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
23
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 18 more
Source: ClinicalTrials.gov public record
Updated May 5, 2020 · Synced Sep 7, 2026, 10:24 AM EDT
Completed Phase 2 Interventional Results available

Comparison of Secukinumab Versus Guselkumab in Clearing Psoriatic Plaques Refractory to Ustekinumab

NCT03553823
View directory record Official record
Conditions
Chronic Plaque-type Psoriasis
Interventions
Skin biopsies
Procedure
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
4
States / cities
New Orleans, Louisiana • East Windsor, New Jersey • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2021 · Synced Sep 7, 2026, 10:24 AM EDT
Completed No phase listed Observational

Genetic and Immune Studies of Rheumatoid Arthritis and Related Conditions

NCT00001291
View directory record Official record
Conditions
Arthritis, Psoriatic, Autoimmune Diseases, Joint Diseases, Osteoarthritis, Rheumatoid Arthritis
Interventions
Not listed
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
1991 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Sep 7, 2026, 10:24 AM EDT
Completed Phase 4 Interventional Results available

A Study to Investigate Efficacy and Safety of VTAMA® (Tapinarof) Cream, 1% in Plaque Psoriasis in the Head and Neck Region

NCT05789576
View directory record Official record
Conditions
Psoriasis
Interventions
VTAMA (tapinarof) cream, 1%
Drug
Lead sponsor
Organon and Co
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
10
States / cities
Macon, Georgia • Chicago, Illinois • Rockville, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2025 · Synced Sep 7, 2026, 10:24 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis

NCT01172938
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Apremilast 20mg, Apremilast 30mg, Placebo + 20 mg Apremilast, Placebo + 30 mg Apremilast
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
504 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
27
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2020 · Synced Sep 7, 2026, 10:24 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions

NCT01931644
View directory record Official record
Conditions
All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis, Asthma, Atopic Dermatitis Eczema, Beta Thalassemia, Bipolar Disorder, Breast Cancer, Celiac Disease, Cervical Cancer, Chronic Inflammatory Demyelinating Polyneuropathy, Chronic Kidney Diseases, Chronic Obstructive Pulmonary Disease, Colon Cancer, Colorectal Cancer, Crohn's Disease, Cystic Fibrosis, Depression, Diabetes Mellitus, Duchenne Muscular Dystrophy, Endometriosis, Epilepsy, Facioscapulohumeral Muscular Dystrophy, G6PD Deficiency, General Anxiety Disorder, Hepatitis B, Hereditary Hemorrhagic Telangiectasia, HIV/AIDS, Human Papilloma Virus, Huntington's Disease, Idiopathic Thrombocytopenic Purpura, Insomnia, Kidney Cancer, Leukemia, Lung Cancer, Lupus Nephritis, Lymphoma, Melanoma, Multiple Myeloma, Multiple Sclerosis, Myositis, Myotonic Dystrophy, Ovarian Cancer, Pancreatic Cancer, Parkinson's Disease, Polycystic Kidney Diseases, Prostate Cancer, Psoriasis, Psoriatic Arthritis, Rosacea, Scleroderma, Sickle Cell Anemia, Sickle Cell Trait, Sjogren's Syndrome, Skin Cancer, Spinal Muscular Atrophy, Systemic Lupus Erythematosus, Thrombotic Thrombocytopenic Purpura, Trisomy 21, Ulcerative Colitis
Interventions
Not listed
Lead sponsor
Sanguine Biosciences
Industry
Eligibility
18 Years to 100 Years
Enrollment
17,667 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Sep 7, 2026, 10:24 AM EDT
Recruiting No phase listed Observational

IMPACT - AndHealth Autoimmune Research Registry

NCT05883371
View directory record Official record
Conditions
Arthritis, Rheumatoid, Arthritis, Psoriatic, Psoriasis, Ankylosing Spondylitis, Autoimmune Diseases
Interventions
Root-cause autoimmune treatment program
Other
Lead sponsor
AndHealth
Industry
Eligibility
18 Years to 70 Years
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Sep 7, 2026, 10:24 AM EDT
Completed Phase 3 Interventional Results available

Open-Label Extension Study Of Tofacitinib In Psoriatic Arthritis

NCT01976364
View directory record Official record
Conditions
Arthritis, Psoriatic
Interventions
Tofacitinib, Methotrexate, Placebo Methotrexate
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
686 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
43
States / cities
Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated May 20, 2020 · Synced Sep 7, 2026, 10:24 AM EDT
Recruiting Phase 4 Interventional

A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)

NCT06864026
View directory record Official record
Conditions
Psoriatic Arthritis, Overweight or Obesity
Interventions
Tirzepatide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
53
States / cities
Avondale, Arizona • Chandler, Arizona • Flagstaff, Arizona + 48 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 7, 2026, 10:24 AM EDT
Recruiting No phase listed Observational

Study to Evaluate Pregnancy Outcomes in Risankizumab Exposed Pregnancies Relative to Those Non-risankizumab Exposed Pregnancies in Women With FDA Approved Indications

NCT04846959
View directory record Official record
Conditions
Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease, or Other Conditions for Which Risankizumab is an FDA-approved Treatment
Interventions
Risankizumab, Comparator
Drug
Lead sponsor
AbbVie
Industry
Eligibility
Female only
Enrollment
818 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2032
U.S. locations
2
States / cities
Morrisville, North Carolina • Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Sep 7, 2026, 10:24 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Pilot Study Characterizing Adipose Tissue Leukocytes by Flow Cytometry/Microscopy in Lean, Obese and Psoriatic Subjects

NCT01856647
View directory record Official record
Conditions
Psoriasis, Obesity
Interventions
Adipose tissue biopsy (fat biopsy)
Procedure
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 20, 2015 · Synced Sep 7, 2026, 10:24 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Subcutaneous Secukinumab for Moderate to Severe Chronic Plaque-type Psoriasis for up to 1 Year

NCT01365455
View directory record Official record
Conditions
Moderate to Severe Plaque-type Psoriasis
Interventions
secukinumab 150 mg, placebo to secukinumab 150 mg
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
738 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
34
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2021 · Synced Sep 7, 2026, 10:24 AM EDT
Completed Phase 3 Interventional Results available

PALACE 2: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis

NCT01212757
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Apremilast 20mg, Apremilast 30mg, Placebo + 20 mg Apremilast, Placebo + 30 mg Apremilast
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
488 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
23
States / cities
Tuscaloosa, Alabama • Denver, Colorado • Trumbull, Connecticut + 18 more
Source: ClinicalTrials.gov public record
Updated May 5, 2020 · Synced Sep 7, 2026, 10:24 AM EDT
Completed Phase 2 Interventional Results available

Low Dose Naltrexone for Chronic Pain From Arthritis

NCT03008590
View directory record Official record
Conditions
Osteoarthritis, Arthritis, Rheumatoid, Arthritis, Psoriatic
Interventions
Naltrexone, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
Not listed
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 2, 2021 · Synced Sep 7, 2026, 10:24 AM EDT
Terminated Phase 1 Interventional

First Human Dose Study of Anti-IL-20 in Psoriasis: A Study of Safety, Tolerability and Early Signals of Biologic and Clinical Effects

NCT01261767
View directory record Official record
Conditions
Inflammation, Psoriasis
Interventions
anti-IL-20, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
16
States / cities
Birmingham, Alabama • Los Angeles, California • Skokie, Illinois + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2017 · Synced Sep 7, 2026, 10:24 AM EDT
Recruiting Not applicable Interventional

Creating Health Course Study for People With Rheumatological Conditions and Mood Disorders

NCT07180537
View directory record Official record
Conditions
Rheumatoid Arthritis, Sjogren's Syndrome, Systemic Lupus Erythematosus, Mixed Connective Tissue Disease, Psoriatic Arthritis, Anxiety Disorders, Depressive Disorders, Moderate Depression, Moderate Anxiety
Interventions
Creating Health Online Course, Delayed access to Creating Health Online Course
Behavioral
Lead sponsor
Terry L. Wahls
Other
Eligibility
18 Years to 100 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 7, 2026, 10:24 AM EDT
Terminated Early Phase 1 Interventional

COVID-19 Vaccination in Rheumatic Disease Patients

NCT04839315
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Sjogren's Syndrome, Inflammatory Myositis, Psoriatic Arthritis, Gout, Ankylosing Spondylitis, Arthritis of Multiple Sites Associated With Inflammatory Bowel Disease (Diagnosis), Osteoarthritis
Interventions
mRNA COVD19 vaccine
Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 2, 2022 · Synced Sep 7, 2026, 10:24 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Psorcast Mobile Study

NCT05621369
View directory record Official record
Conditions
Psoriatic Arthritis, Psoriasis, Psoriatic Conditions, Dermatologic Disease, Rheumatologic Disease, Psoriatic Nail, Plaque Psoriasis, Joint Pain, Dactylitis
Interventions
Participant self-assessment surveys, Psoriasis Draw, Psoriasis Area Photo, Finger and Toe Photos, Digital Jar Open, 30 Second Walk, Psorcast mobile application
Behavioral · Other
Lead sponsor
Sage Bionetworks
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Sep 7, 2026, 10:24 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Web-based Support to Manage Arthritis Pain

NCT01463189
View directory record Official record
Conditions
Osteoarthritis, Rheumatoid Arthritis, Ankylosing Spondylitis, Other Arthritic Conditions (e.g., Psoriatic Arthritis)
Interventions
painACTION: Arthritis
Behavioral
Lead sponsor
Inflexxion, Inc.
Industry
Eligibility
18 Years and older
Enrollment
228 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Newton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 9, 2012 · Synced Sep 7, 2026, 10:24 AM EDT
Active, not recruiting Not applicable Interventional

Prevention of Cardiovascular Disease and Mortality in Patients With Psoriasis or Psoriatic Arthritis

NCT05908240
View directory record Official record
Conditions
Psoriasis, Psoriatic Arthritis, Psoriatic Conditions, Cardiovascular Diseases
Interventions
Care Coordinator Model
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
40 Years to 75 Years
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
20
States / cities
Scottsdale, Arizona • Fort Smith, Arkansas • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 7, 2026, 10:24 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Subclinical Cardiovascular Disease in Psoriatic Disease

NCT03228017
View directory record Official record
Conditions
Cardiovascular Diseases, Myocardial Infarction, Atherosclerotic Cardiovascular Disease, Thrombotic Vascular Disease
Interventions
Aspirin and/or Atorvastatin
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 90 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 27, 2021 · Synced Sep 7, 2026, 10:24 AM EDT